Last reviewed · How we verify
NCT04842513: GLIO-XS15
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
Phase 1 trial testing Multipeptide plus XS15 in Glioblastoma Multiforme of Brain in 15 participants. Completed in 31 July 2024.
31 July 2024
Quick facts
| Lead sponsor | University Hospital Tuebingen |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 3 May 2021 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Multipeptide plus XS15 — full drug profile →
Conditions studied
- Glioblastoma Multiforme of Brain — all drugs for Glioblastoma Multiforme of Brain →
Sponsor
University Hospital Tuebingen
Who can join
18 and older, any sex, with Glioblastoma Multiforme of Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7 -
Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A, Sun L, Lin H, Liao Y, et al · · 2024 · cited 150× · PMID 38523155 · DOI 10.1038/s41392-024-01765-9 -
Development of Peptide-Based Vaccines for Cancer.
Abd-Aziz N, Poh CL. · · 2022 · cited 100× · PMID 35342400 · DOI 10.1155/2022/9749363 -
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
Xun Y, Yang H, Kaminska B, You H. · · 2021 · cited 96× · PMID 34715891 · DOI 10.1186/s13045-021-01191-2 -
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D, Bolyard C, Wu BX, Cam H, et al · · 2022 · cited 53× · PMID 35690784 · DOI 10.1186/s13045-022-01298-0 -
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
Salvato I, Marchini A. · · 2024 · cited 32× · PMID 38610954 · DOI 10.3390/cancers16071276 -
Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4<sup>+</sup> and CD8<sup>+</sup> T cells for immunotherapy of cancer.
Melssen MM, Fisher CT, Slingluff CL, Melief CJM. · · 2022 · cited 30× · PMID 36939214 · DOI 10.1136/jitc-2022-004709 -
Therapeutic approaches to modulate the immune microenvironment in gliomas.
Sarantopoulos A, Ene C, Aquilanti E. · · 2024 · cited 19× · PMID 39443641 · DOI 10.1038/s41698-024-00717-4
Verify or expand the search:
- PubMed search for NCT04842513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma Multiforme of Brain
Currently open trials in the same condition.
- NCT06815432 — GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma · Phase 1 · recruiting
- NCT06613841 — Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma · EARLY_PHASE1 · recruiting
- NCT06283927 — The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) · recruiting
- NCT06273176 — The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma · recruiting
- NCT06146725 — The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) · recruiting
Other University Hospital Tuebingen trials
Trials by the same sponsor.
- NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
- NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
- NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04842513 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
- Last refreshed: 10 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04842513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing